Answers are grounded in this paper and cite their sources.
Machine learning (ML) accelerates PROTAC design by optimizing linkers and protein–ligase interactions, enabling selective protein degradation for therapeutic applications, particularly targeting previously undruggable proteins.
No takes yet. Share an insight, caveat, or question.
Gharbi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: